Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript

SA Transcripts158.45K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Genmab A/S (GMAB) Q4 2025 Earnings Call February 17, 2026 12:00 PM EST Company Participants Jan van de Winkel - Co-Founder, President & CEOBrad BaileyAnthony Pagano - Executive VP & CFOTahamtan Ahmadi - Executive VP, Chief Medical Officer & Head of Experimental MedicinesJudith Klimovsky - Executive VP & Chief Development Officer Conference Call Participants Jonathan Chang - Leerink Partners LLC, Research DivisionAsthika Goonewardene - Truist Securities, Inc., Research DivisionXian Deng - UBS Investment Bank, Research DivisionRajan Sharma - Goldman Sachs Group, Inc., Research DivisionJudah Frommer - Morgan Stanley, Research DivisionJames Gordon - Barclays Bank PLC, Research DivisionZain Ebrahim - JPMorgan Chase & Co, Research DivisionSuzanne van VoorthuizenYaron Werber - TD Cowen, Research DivisionQize Ding - Rothschild & Co Redburn, Research DivisionMatthew Phipps - William Blair & Company L.L.C., Research DivisionVictor Floch - BNP Paribas, Research DivisionMattias Häggblom - Handelsbanken Capital Markets AB, Research DivisionBenjamin Jackson - Jefferies LLC, Research Division Presentation Operator Hello, and welcome to the Genmab Full Year 2025 Financial Results Conference Call. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. Genmab is not under any obligation to update statements regarding the future nor to confirm such statements in relation to actual results, unless this is required by law. Please also note, Genmab may hold your personal data as indicated by you as a part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy. I would now like to hand the conference over to our first speaker today, Jan van de Winkel. Please